| Revenue growth | FY26 growth 27.5%; FY27 target INR 17,000-18,000 Cr. |
|---|---|
| Margins | FY27 EBITDA margin guided at 21-22%. |
| Demand visibility | Strong uptake for TEVIMBRA/BRUKINSA; RYALTRIS momentum continues globally. |
| Management confidence | High, citing innovative oncology pipeline and U.S. respiratory launches. |
Growth
FY26 Revenue: INR 1,69,825 Mn (up 27.5% YoY). India business grew 1.5x market rate.
Outlook
FY27 Revenue guidance: INR 17,000-18,000 Cr; EBITDA margin 21-22%. Target gross debt-free status maintained.
Risks
U.S. growth impacted by approval timing and supply chain disruptions; geopolitical war-related collection delays in MEA.
Earnings Call filed with BSE, NSE: GLENMARK. Summary written with AI assistance from the document.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,282.30
- Market cap
- ₹64,412 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 35.8×Sector 47.4×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 20.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals Annual General Meeting
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
Glenmark Pharmaceuticals Credit Rating
India Ratings upgraded Glenmark Pharmaceuticals' long-term bank loans to 'IND AA+' and affirmed short-term ratings at 'IND A1+'.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP in various dosages. This launch expands the company's injectable portfolio and presence in the U.S. hospital market.
Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received U.S. FDA approval for its Fluticasone Propionate Nasal Spray. The product will be distributed in the U.S. market.